What the FDA labels say about taking them together
Rifampin and tofacitinib
Tofacitinib's FDA label of July 13, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name tofacitinib. The tofacitinib label: “… modification of XELJANZ/XELJANZ XR is recommended Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response Intervention Concomitant …”
Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the tofacitinib FDA label on DailyMed (effective July 13, 2026, U.S. Pharmaceuticals).
What does the rifampin label say about tofacitinib?
Rifampin's label (effective February 11, 2026) does not name tofacitinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
What does the tofacitinib label say about rifampin?
Tofacitinib label, drug interactions… fluconazole) Clinical Impact Increased exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3) ] Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response Intervention Concomitant use with XELJANZ/XELJANZ XR is not recommended [see Clinical Pharmacology, Figure 3 (12.3) ] Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine) Clinical Impact Risk of added immunosuppression; …
Source: FDA drug label (XELJANZ), NDA203214 (Pf Prism Cv), as published by U.S. Pharmaceuticals, effective July 13, 2026 (SPL set 68e3d6b2-7838-4d2d-a417-09d919b43e13), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifampin | Tofacitinib | |
|---|---|---|
| Labeled for | n/a | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.679 per capsule 300 mg capsule | $0.573 per tablet 5 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once